Expertise in
4
conditions

Shailendra P. Verma

Lucknow, UP, IN 
Expertise in
4
conditions
Lucknow, UP, IN 

Overview

Shailendra Verma practices practicing medicine in Lucknow, India.

Verma is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Aplastic Anemia, Chronic Myelogenous Leukemia (CML), Anemia, Blood Clots, and Bone Marrow Aspiration.

They are actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 2 clinical trials.

Locations

Lucknow, UP, India
Other Locations
Puducherry, PY, India
UP, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 1 Less Clinical Trial

72 Total Publications

Correction: FBW7 Inhibits Myeloid Differentiation in Acute Myeloid Leukemia via GSK3-Dependent Ubiquitination of PU.1.
Correction: FBW7 Inhibits Myeloid Differentiation in Acute Myeloid Leukemia via GSK3-Dependent Ubiquitination of PU.1.
Journal: Molecular cancer research : MCR
Published: August 04, 2026

Frequently Asked Questions about Shailendra P. Verma

Is Shailendra P. Verma a top-rated expert for Aplastic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Shailendra P. Verma is classified as an Advanced expert for Aplastic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Shailendra P. Verma participate in research or clinical trials?

Yes. Shailendra P. Verma has published 72 articles and abstracts on conditions like Aplastic Anemia. You can view a list of Shailendra P. Verma's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Verma's expertise for a condition
ConditionClose
      View All 48 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile